Esaote Presents MyLab™X90 – New Premium Ultrasound System

An innovative premium system combining outstanding performance with artificial intelligence to optimize workflows and support advanced and interconnected healthcare systems

Today Esaote, a leading Italian company in the biomedical sector – in ultrasound, dedicated MRI and medical IT– presents the world premiere of MyLab™X90, its new premium ultrasound system.

“Accuracy and precision across the entire image generation chain, data processing speed and native AI-based application management lie at the heart of MyLab™X90,” said Guillaume Gauthier, Ultrasound Global Product Marketing Manager. “As well as providing high-quality images and advanced clinical solutions, our aim was to revolutionize daily workflows by increasing the speed and accuracy of analysis, together with improving the operator experience and the clinical outcome for patients.”

MyLab™X90 offers premium components, where the starting points are the renewal of the XCrystal probe family and the exclusive dual-layer eLed monitor by Barco. These ensure outstanding on-screen image display at a very high contrast resolution, far superior to other product lines.

MyLab™X90 also offers advanced ergonomics in clinical solutions focused on the operator, which extend data analysis capacity and ensure a unique customer experience based on diagnostic confidence, as well as on automation to improve the usability and availability of advanced technologies in everyday clinical practice.

“We are highly satisfied with this outcome, the result of substantial investment and intense work on R&D. The new MyLab™X90, with its all-Italian design, represents a further evolution in the range of technologies we provide to assist with people’s care and well-being,” noted Franco Fontana, CEO of Esaote. “It represents the upshot of strategic investment and of our international, multidisciplinary team, who can tackle the challenges of innovation and anticipate requirements in the most advanced and interconnected healthcare systems. We believe that these aspects, combined with the latest technologies, can contribute significantly to improving the level of patient care, and are delighted to play an active role.”

For its world premiere Esaote selected Manama, an international context and a vibrant multicultural hub. The event, that will be attended by the Bahraini authorities and by international clinical experts will be livestreamed on Esaote LinkedIn page (https://www.linkedin.com/events/mylab-x90livestreaming-a-i-augm7021420599726026753/) and will then be available on demand at mylabx90.com .

The new MyLab™X90 will be showcased at Arab Health 2023 (Dubai, January 30 – February 2), and at the European Congress of Radiology (ECR) 2023, in Vienna from March 1 to 5.

510(k) pending at FDA, not available for sale in USA.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.